Greenland Mines Ltd. (NASDAQ: GRML) has been granted a patent by Innovation, Science and Economic Development Canada covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. This milestone is significant as it strengthens Greenland Mines' position in the biotech sector, particularly in the development of treatments for devastating neurodegenerative conditions. The patent protection in Canada, a key market for pharmaceutical innovation, provides a competitive advantage and potential barriers to entry for competitors.
Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. The advancement of KLTO-202, which targets ALS, into GMP manufacturing marks a critical step toward clinical trials, bringing the company closer to delivering a potential therapy for a disease with high unmet medical need.
The implications of this announcement are twofold. First, it underscores the company's commitment to building a robust IP portfolio around Klotho-based therapies, which are seen as a promising approach for treating neurodegenerative diseases. Second, the progress of KLTO-202 into GMP manufacturing signals that Greenland Mines is transitioning from research to clinical development, a key value inflection point for the company. For investors, this news may enhance confidence in the biotech division's potential, complementing the company's mining operations in Greenland focused on rare earth materials.
The full press release is available at https://ibn.fm/x2pHA. For more information about Greenland Mines, visit the company's newsroom at https://ibn.fm/GRML.
